The interaction of caffeine, theophylline and theobromine with monoamine oxidase inhibitors.

Abstract The toxicity of caffeine, theophylline and theobromine was increased by the monoamine oxidase inhibitors pargyline, iproniazid, tranylcypramine and β-phenylisopropylhydrazine in the rat. The hypokinesia, ptosis and hypothermia following caffeine were replaced by agitation, disorientation and hyperthermia following caffeine plus pargyline. Antiserotonergic drugs were more effective than symphatholytic drugs in preventing alterations in temperature, homeostasis and the lethal consequences of the drug interaction. Serotonin may play a role in the pharmacologic action of caffeine.

[1]  J. Axelrod,et al.  The fate of caffeine in man and a method for its estimation in biological material. , 1953, The Journal of pharmacology and experimental therapeutics.

[2]  P. Bradley,et al.  Antagonism of 5‐hydroxytryptamine by LSD 25 in the central nervous system: a possible neuronal basis for the actions of LSD 25 , 1970, British journal of pharmacology.

[3]  B A Berkowitz,et al.  The effect of caffeine and theophylline on the disposition of brain serotonin in the rat. , 1971, European journal of pharmacology.

[4]  L. I. Goldberg,et al.  MONOAMINE OXIDASE INHIBITORS. ADVERSE REACTIONS AND POSSIBLE MECHANISMS. , 1964, JAMA.

[5]  A. Pletscher.  SIGNIFICANCE OF MONOAMINE OXIDASE INHIBITION FOR THE PHARMACOLOGICAL AND CLINICAL EFFECTS OF HYDRAZINE DERIVATIVES , 1959, Annals of the New York Academy of Sciences.

[6]  A. Horita,et al.  The pyretogenic effect of 5-hydroxytryptophan and its comparison with that of ISD. , 1958, The Journal of pharmacology and experimental therapeutics.

[7]  W. D. Reid,et al.  Turnover rate of brain 5‐hydroxytryptamine increased by D‐amphetamine , 1970, British journal of pharmacology.

[8]  J. A. Parsons.  Drug Dosage in Laboratory Animals , 1965, Nature.

[9]  B. Levy.  The adrenergic blocking activity of N-tert.-butylmethoxamine (butoxamine). , 1966, The Journal of pharmacology and experimental therapeutics.

[10]  E M Boyd,et al.  THE CHRONIC ORAL TOXICITY OF CAFFEINE , 1965 .

[11]  R. Butcher,et al.  Adenosine 3',5'-phosphate in biological materials. I. Purification and properties of cyclic 3',5'-nucleotide phosphodiesterase and use of this enzyme to characterize adenosine 3',5'-phosphate in human urine. , 1962, The Journal of biological chemistry.

[12]  B A Berkowitz,et al.  Release of norepinephrine in the central nervous system by theophylline and caffeine. , 1970, European journal of pharmacology.

[13]  M. Rand,et al.  The mechanism of the augmentation of responses to indirectly acting sympathomimetic amines by monoamine oxidase inhibitors. , 1968, British journal of pharmacology and chemotherapy.

[14]  J. Vernikos-Danellis,et al.  Effect of environmental temperature on the toxicity of caffeine and dextroamphetamine in mice. , 1970, The Journal of pharmacology and experimental therapeutics.

[15]  A. Weissman,et al.  p-Chlorophenylalanine: a specific depletor of brain serotonin. , 1966, The Journal of pharmacology and experimental therapeutics.

[16]  W. Y. Cheung,et al.  Properties of cyclic 3',5'-nucleotide phosphodiesterase from rat brain. , 1967, Biochemistry.

[17]  S. Spector,et al.  Effect of caffeine and theophylline on peripheral catecholamines. , 1971, European journal of pharmacology.

[18]  N. Kline.  Psychopharmaceuticals: effects and side effects. , 1959, Bulletin of the World Health Organization.